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Design, development, testing at ISO standards and
in vivo feasibility study of a novel polymeric heart
valve prosthesis†
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Clinically available prosthetic heart valves are life-saving, but imperfect: mechanical valves requiring antic-
oagulation therapy, whilst bioprosthetic valves have limited durability. Polymer valves offer the prospect of
good durability without the need for anticoagulation. We report the design and development of a poly-
meric heart valve, its bench-testing at ISO standards, and preliminary extra-vivo and in vivo short-term
feasibility. Prototypes were manufactured by injection moulding of styrenic block copolymers to achieve
anisotropic mechanical properties. Design was by finite element stress–strain modelling, which has been
reported previously, combined with feedback from bench and surgery-based testing using various combi-
nations of materials, valve geometry and processing conditions. Bench testing was according to ISO
5840:2015 standards using an in vitro cardiovascular hydrodynamic testing system and an accelerated
fatigue tester. Bench comparisons were made with a best-in-class bio-prosthesis. Preliminary clinical
feasibility evaluations included extra-vivo and short-term (1–24 hours) in vivo testing in a sheep model.
The optimised final prototype met the requirements of ISO standards with hydrodynamic performance
equivalent to the best-in-class bioprosthesis. Bench durability of greater than 1.2 billion cycles (30 years
equivalent) was achieved (still ongoing). Extra-vivo sequential testing (n = 8) allowed refinement of exter-
nal diameter, 3D shape, a low profile, flexibility, suturability, and testing of compatibility to magnetic reso-
nance imaging and clinical sterilisation. In vivo short-term (1–24 hours) feasibility (n = 3) confirmed good
suturability, no mechanical failure, no trans-valvular regurgitation, competitive trans-valvular gradients,
and good biocompatibility at histopathology. We have developed and tested at ISO standards a novel
prosthetic heart valve featuring competitive bench-based hydrodynamics and durability, well beyond the
ISO requirements and comparable to a best-in-class bioprosthesis. In vivo short-term feasibility testing
confirmed preliminary safety, functionality and biocompatibility, supporting progression to a long-term
efficacy trial.
Introduction
The search for the ideal prosthetic heart valve combining
excellent durability and biocompatibility is still on. Despite the
development of transcatheter devices, surgically implanted
mechanical and bioprosthetic valves still represent the great
majority of heart valve replacements.1,2 Approximately 80% of
surgical prostheses currently implanted are tissue valves,3 with
the use of mechanical valves gradually declining.
The usual lifespan of bioprosthetic valves is 10–15 years.
While they feature good biocompatibility and no need for
anticoagulation, their risk of structural deterioration is an
issue, particularly in young patients or due to exacerbated
calcification.4,5 Mechanical valves have excellent durability,
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but require anticoagulation, causing significant haemorrhagic
or thromboembolic risks, resulting from the thrombogenicity
of materials and high shear stresses, particularly around the
hinge points, which damages blood and activates clotting.6
Polymeric heart valves (PHVs) are predominantly con-
structed of polymer-based materials which have good biocom-
patibility and biostability.7 They may combine the advantages
of mechanical and bioprosthetic valves, hence with potential
to impact on patient wellbeing. Unlike the laborious hand
sewing of biological tissue onto frames, PHVs can be manufac-
tured using simple and automated fabrication techniques and
can therefore be significantly less expensive and with better
quality control. There has been a substantial work in recent
years to develop a PHV7,8 but none has yet reached the clinic,
although recently the Foldax Tria surgical polymeric valve
(https://foldax.com/) has undergone first-in-human implan-
tation, with no data published yet. As well as valves for surgical
implantation which is the topic of this paper, polymeric leaf-
lets also show promise for trans-catheter valves.9,10
Styrenic triblock copolymers (STCPs) are synthetic thermo-
plastic elastomers amenable to high-throughput injection
moulding, with applications in medicine, for example in a
commercial drug-eluting coronary stent.11 They contain poly-
styrene hard domains in a continuous elastomeric phase; with
the hard domains forming physical cross-links and providing
strength, while the elastomeric phase gives flexibility and elas-
ticity. Altering the relative fraction of hard and soft segments
results in a range of morphologies at the nano-scale, driven by
the immiscibility of the different blocks. Thus by selecting
different block copolymers with specific molecular weights
and styrene fractions12 it is possible to manufacture a whole
3D dynamic PHV, featuring two or more levels of flexibility in
stent and leaflet areas. In addition, STCPs with a styrene
content in the range 20–33% self assemble into cylindrical
microstructure; and hot melt processing of such STCPs with
cylindrical microstructure can produce structural anisotropy,
with different mechanical properties in two orthogonal
directions,13–15 mimicking the mechanics of native heart valve
tissue.16,17 Finite element modelling has shown that, if cor-
rectly distributed within a heart valve leaflet, such anisotropy
substantially reduces the peak strain energy density the
material is exposed to and so may enhance durability.18
Previous publications explain how such a desirable distri-
bution of anisotropy may be obtained by injection moulding
of STCPs.19,20 The benefits of such an anisotropic microstruc-
ture is confirmed by a recent report of an anisotropic silicone
valve, manufactured by additive manufacturing techniques.21
The estimated number of patients per year requiring heart
valve replacements by 2050 is >1 million.22 Being inexpensive,
while combining durability and biocompatibility, a novel PHV
could benefit young and elderly patients globally with a one
type-fit-all approach.
Here we describe the design, development and testing of a
novel PHV, named Poli-Valve,23 manufactured by injection mould-
ing of styrenic triblock copolymers with cylindrical microstructure.
This cylindrical microstructure is formed by self-assembly resulting
from the segregation of the styrenic and elastomeric blocks of the
triblock copolymers: the cylinders are of well-defined diameter
(order 10 nm) and spacing (order 20 nm), and having a high
aspect ratio; the cylinders may be preferentially oriented by melt
flow.19 The new valve is entirely polymeric with only two structural
components: leaflets and stent, made from different grades of the
same material.
Haemocompatibility of a selection of styrenic block copoly-
mers has previously been tested in vitro using a modified
Chandler loop according to ISO 10993:4 and is reported else-
where.24 The work shows that styrenic block copolymers tested
elicited no adverse host response in haemocompatibility or
direct fibroblast contact. Measures of platelet and coagulation
cascade activation indicated that the test materials were
superior to polyester and similar to bovine pericardium refer-
ence materials. Inflammatory measures showed minimal hae-
molysis and immune system activation better than for poly-
ester and bovine pericardium. Moreover, the addition of a
heparin coating further reduced protein adsorption and
improved ex vivo haemocompatibility performance in all
measures. A similar block copolymer, SIBS, has also been
shown to have low thrombogenic activity.25,26
Methods
PHV design, bench-based development and evaluations
Materials. In valve development we have used commercial
block copolymers poly(styrene-block-ethylene/propylene-block-
styrene) (SEPS) and poly(styrene-block-ethylene/butylene-block-
styrene) (SEBS) manufactured by Kraton. Although their intended
use is mainly in automotive, adhesives, compounding etc., they are
pure synthetic materials, obtainable in many grades in the market.
For the time being, the manufacturer does not provide them for
use as permanent biomedical implants; however, there are a
number of other medical applications, and we have established a
collaboration with Kraton to explore the use of their polymers in
heart valve prostheses. Synthesis of the block copolymers is well
known27 and an equivalent to the best performing commercial
material could be purposely made for use in heart valves, should
this be necessary.
Molecular characterisation of the block copolymers
(Table 1) was evaluated by gel permeation chromatography
(GPC) using triple detection on a Viscotek GPCmax VE2001












71 697 1.038 19.2
SEBS29 Poly(styrene-block-ethylene/
butylene-block-styrene)
74 837 1.061 28.4
SEBS20 Poly(styrene-block-ethylene/
butylene-block-styrene)
111 327 1.072 19.6
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GPC Solvent/Sample Module. The detectors used were: refrac-
tive index, viscosity and light scattering. Tetra-hydro-furan was
the eluent (flow 1 ml min−1) at a constant temperature of
24 °C. The detectors were calibrated with polystyrene standard
Malvern PolyCal™ Std-PS99k. The values for the refractive
index increment (dn/dc) used for the calculation were 0.185 ml
g−1 for polystyrene and 0.072 ml g−1 for both ethylene-butylene
and ethylene–propylene blocks.
Microstructure characterisation of the block copolymers
and structural alignment in the heart valve leaflets was evalu-
ated by Small Angle X-ray Diffraction using the Bruker
Nanostar instrument.
Design, prototyping, relative costs and timing. Prototype
designs were refined with the aid of computational modelling,
fully described elsewhere.18,28 Briefly, this resulted in develop-
ment of a computational tool to optimize the alignment of
cylindrical domains along directions of maximum stress,
mimicking the alignment of collagen bundles in natural heart
valve leaflets. This optimized alignment resulted in minimis-
ation of strain energy density, which in turn is expected to
maximise durability.
PHVs were manufactured by injection moulding. Briefly,
the overall process cycle comprises the following steps:
melting of block copolymer granules, injection into the
mould cavity in the form of a viscoelastic polymer flow,
packing, cooling, and removing of the moulded part. The
method offers relatively inexpensive and highly reproducible
manufacturing. The injection was achieved through a
channel narrowing from diameter 2 mm to 0.4 mm, which
minimised the size of the sprue. The reduction of the
channel helped also to detach the sprue spontaneously,
leaving only about 1 mm of excess material sticking out of
the heart valve leaflet’s surface.
In the process of prototyping, making of injection mould-
ing tools is the most laborious and expensive stage, especially
when the tools are made in stainless steel by commercial
mould manufacturers, such as those used for the prototypes F
and B (see Table 2).
In order to reduce costs and manufacturing time a new
machining process was adapted from aerospace machining
techniques used by the Whittle Laboratory at the University of
Cambridge. These tools (Fig. 1A) are made in aluminium alloy
and by five axis CNC machining. This allows shorter, stiffer
cutters to be used to mill the mould which results in improved
surface finish, accuracy, reduced machining cycle time and
therefore lower cost. The decision to use the new process
allowed more valve designs to be tested in the project. After
preliminary mathematical modelling studies and initial proto-
type testing ex vivo, the design was further refined based on
clinician feedback.
Prototype valves selected for animal trials, have been
heparin coated using either Corline Heparin Conjugate CHC™
(Corline Biomedical AB, Sweden) or Astute® Advanced
Heparin Coating (Biointeractions Ltd, UK). Finally, the valves
have been sterilised with ethylene oxide shortly before the
surgery.
Relative costing and timing necessary for valve production
was assessed to inform the future financial case of our device
toward clinical impact and commercialisation.
Durability. Durability of the PHV prototypes was assessed in
an accelerated fatigue tester (TA Electroforce) at 30 Hz with
water at 37 °C as the working fluid, under test conditions
specified by ISO 5840:2015, which requires 100 mmHg
pressure difference across the closed aortic valves for at least
5% of each cycle, and this should be maintained for more
than 95% of all test cycles (Video 1, ESI†). The durability
testing of the latest prototype J6 (n = 4) has taken 17 months to
complete, which explains the relatively high testing frequency
chosen. Valves were videoed under stroboscopic illumination
in the accelerated fatigue tester, and the extent of opening at
various frequencies could not be distinguished; the mean geo-
metric orifice area expressed as a percentage of the mean geo-
metric at 30 Hz (±standard deviation) measured using two
different sample valves in two different testing chambers was
98% (±3%) at 25 Hz, 101% (±6%) at 20 Hz and 96% (±4%) at
15 Hz. Each valve was mounted in an independently controlled
testing chamber, where removal or adjustment of one sample
did not affect other samples. Valve failure was identified by
abnormal proximal and distal pressure traces, followed by
visual inspection. Durability test outcome for the earlier proto-
types is reported for the following models: B (n = 8), F (n = 11),
J1 (n = 8), J2 (n = 8), J3 (n = 5), J4 (n = 3) and J5 (n = 11).
Hydrodynamic performance. Hydrodynamic performance of
the PHVs at the bench was evaluated in a pulse duplicator
system according to methods described elsewhere.23 Briefly,
the pulse duplicator comprises of a volumetric pumping
system, a ventricular chamber, an aortic valve housing, a three
parameters systemic impedance simulator and a mitral valve
housing. The pulse duplicator is able to reproduce the physio-
logical stroke volume, pressure and flow waveforms of the left
ventricle of the human heart. The PHVs were tested in the
aortic position with a mechanical, tilting disc valve mounted
in the mitral position with water at 20 °C as the working fluid.
The test conditions conformed to ISO 5840:2015 requirements
i.e. frequency of 70 bpm, simulated cardiac output 5 l min−1,
systolic duration 35% at normotensive conditions (Video 2,
ESI†). Simultaneous flow and pressure measurements
upstream and downstream from the aortic valve were recorded
by using Transonic ultrasound flowmeters and pressure trans-
ducers, respectively. Bench-based hydrodynamic performance
of each valve was evaluated, as per ISO 5840-2:2015, by calcu-
lating Effective Orifice Area (EOA) according to eqn (1), average








where the EOA is calculated in cm2, QRMS is the root mean
squared forward flow (ml s−1) during the positive differential
pressure period (ΔP > 0), ΔP (mmHg) is the mean pressure
difference (measured during the positive differential pressure
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period), and ρ (g cm−3) is the density of the test fluid. The eval-
uated regurgitant fraction included closing volume, transvalvu-
lar leakage volume and paravalvular leakage volume, and is
expressed as a percentage of the forward flow volume.
Comparisons were made between similar PHVs with differ-
ences in leaflet thickness and between the J5 (n = 6 for each
thickness) and J6 (n = 13) prototypes vs. the best-in-class and
most commonly used bio-prosthesis (BIC-B, n = 2), namely the
Carpentier-Edwards Perimount Pericardial Bioprosthesis.
Haemocompatibility. Thrombus formation was assessed
using the Badimon chamber, which records thrombogenicity
of flowing blood in patients with coronary artery disease29–31
and the efficacy of antithrombotic agents.32–34
For this study, 10 healthy subjects (demographic data see
ESI Table S1†) with no known history of coronary artery
disease, diabetes mellitus, haematological dyscrasias or on
blood thinning medications were recruited.
In brief, a pump was used to draw blood from the antecubi-
tal vein through a series of three cylindrical perfusion
chambers maintained at 37 °C in a water bath. The three per-
fusion chambers are arranged in series with blood flowing
initially through the first, low shear and then the second and
third high shear chambers. Strips of material, cut to fit inside
the chambers, acted as the thrombogenic substrate. The rheo-
logic conditions in the first chamber simulate those of patient
coronary arteries (low shear rate, approximately 212 s−1),
whereas those in the second and third chambers simulate
those of mildly stenosed coronary arteries (high shear rate,
approximately 1690 s−1). The model thus acts as one of deep
coronary arterial injury. Each study lasted for 5 min, during
which flow was maintained at a constant rate of 10 mL min−1.
All studies were performed using the same perfusion chamber
and by the same operator. Immediately after each study, strips
of material were removed and fixed in 4% paraformaldehyde.
Strips of thrombus laden polymer were fixed using 10%
neutral buffered formalin without paraffin processing. The
polymer material was not resistant to xylene which is used as a
clearing reagent. Consequently, it was not possible to paraffin
process the material which is our usual process when using
porcine aorta.
Neutral buffered formalin was used as it resulted in less
cracking of the clotted blood and better retention on the
polymer when compared to test samples using 99% alcohol,
then transferring directly to water-based staining reagents.
Test samples were stained with Masson Trichrome to ident-
ify fibrin.
Study samples were stained by adding staining reagents
directly to the labelled pots containing the polymer, rather
than affixing the polymer to slides. This was done to overcome
the difficulty of handling the delicate polymer strips without
damaging any affixed clotting material. The polymer was
handled using forceps where necessary, and the polymer and
pots were rinsed in running water between staining steps. The
following staining steps were performed:
Chromium trioxide – 60 min
Bleach in sodium metabisulphite – 1 min
Weigerts haematoxylin – 15 min
Blue in Scott’s tap water
Ponceau-acid fuchsin – 3 min
Differentiate in phosphomolybdic acid – 10–20 min
0.25% light green – 10–20 min
The samples were dehydrated in graded alcohols then air-
dried, omitting the final xylene step. Once dry, the polymer
was mounted on plain glass microscope slides using Pertex
mountant and cover slipped.
Images were captured using an Olympus BX51 optical
microscope with a Nikon DS-Fi2 microscope camera.
Preliminary clinical feasibility evaluations
Preliminary clinical feasibility evaluations consisted of extra-
vivo (porcine/sheep hearts, animal cadavers), and in vivo
(sheep) and bench-based evaluations. Extra-vivo refinement
focused on shape, height/profile, external diameter, flexibility,
and suturability (n = 8) and included prototypes J3, J4 and J6.
Key goals were 1. To achieve the smallest possible external dia-
meter at a given effective orifice area; 2. To obtain an elastic/
flexible PHV able to follow in vivo the systolic-diastolic motion
of the aortic annulus; 3. To achieve a fabric-free suturing
system. In addition, we assessed the compatibility of the PHV
with magnetic resonance imaging (MRI) and clinical steriliza-
Fig. 1 Manufacturing of J6 PHV: (A) aluminium mould inserts for the J6 valve; (B) CAD design; (C) J6 valve with preformed suturing holes (left); and
with “skirt” for clamping into in vitro testing equipment (right).
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tion techniques, which consisted of sterility testing and serial
bench-based evaluations of durability and hydrodynamic per-
formance with and without sterilisation (these results are
reported in Table S2, ESI†). The in vivo preliminary safety/feasi-
bility pilot study consisted of short-term basic evaluations
assessing functional (echocardiography) and biocompatibility
performance (PHV clotting at histopathology) of J6 prototype
in a sheep model (n = 3) with recovery ranging from 1 hour (n
= 2) to 24 hours (n = 1) after cardiac surgery with cardiopul-
monary bypass (CPB) and cardioplegic arrest (CA), through left
thoracotomy. The case to be recovered for 24 hours post-
surgery was managed only with aspirin 300 mg day−1. The
rationale for this early feasibility study was to ensure safety by
assessing in vivo function with a view to get clearance toward a
subsequent long-term experimental trial.
The animal procedures were undertaken at the University of
Bristol Translational Biomedical Research Centre (TBRC), a
preclinical large animal facility operating at Home Office,
Good Laboratory Practice and clinical healthcare standards. All
procedures were approved by the University of Bristol Research
Ethics committee and performed in accordance with the
Guide for the Care and Use of Laboratory Animals and the
United Kingdom Animal (Scientific Procedures) Act, 1986,
under Home Office Project Licence PPL 7008975.
Results
PHV design and bench-based development and evaluations
Design, prototyping, relative costs and timing. A summary
of the geometric and manufacturing features explored in devel-
opment of our valve prototype is presented in Table 2.
Precision mould machining required only one week from
design to implementation, allowing the testing of a wide range
of geometric features, giving iterative improvements to the per-
formance of the prototype valves. Development was also
informed by clinician/surgical feed-back. This development
process led to the latest design J6 (Fig. 1B and C), which was
the result of testing various leaflet shapes and heights, mould-
ing methods and block copolymers to achieve a clinically
effective PHV.
The J6 design is manufactured by over-moulding SEBS20
(containing 20 wt% styrene) leaflets onto a previously fabri-
cated SEBS (containing 29 wt% styrene) stent and is the proto-
type taken into in vivo feasibility testing. Similarly to collagen
fibre orientation in native heart valve tissue, the orientation of
styrene cylinders in the PHV leaflets is crucial to the valve’s
performance.18,35 The closest analogy to the microstructure of
the native heart valve was achieved by polymer injection into
the middle of each valve leaflet. The microstructure orientation
for J6 leaflet is shown in Fig. 2.
The leaflet was X-ray scanned with 1 mm and 2 mm spatial
interval in horizontal and vertical directions, respectively and
the microstructure in Fig. 2 is represented by a vector graph,
where the angle of the vectors corresponds to the actual orien-
tation of the styrene cylinders and the length of the vectors is
proportional to the azimuthal peak integral. The area above
the injection point shows mostly circumferential orientation of
cylinders, similar to collagen fibres orientation in the native
heart valve tissue. Below the injection point a bi-modal orien-
tation was formed, with part of the material aligned along the
flow and part transverse to the flow direction. Formation of the
bi-modal orientation by shear and extensional flow of the
polymer melt in the mould, has been reported in detail else-
where.19 The ordering of the cylinders was enhanced by
10 minutes annealing of the polymer, taking place during slow
mould cooling after the injection moulding. Such microstruc-
ture also exists in the natural heart valve leaflet tissue, where
circumferentially arranged collagen fibres coexist with radially
oriented elastin layer. The possibility of manufacturing
materials, having such a bio-inspired microstructure, in one
simple moulding process, is believed to be highly
advantageous.
Due to the small size of the valve leaflets and complex distri-
bution of orientation, we have not been able to directly correlate
orientation with mechanical properties in the leaflets themselves.
However, we have done extensive experimental13–15,19,20 and
modelling18,35 work to demonstrate the relationship between orien-
tation and mechanical properties (and so durability) on larger flat
samples.
The cost of valve manufacture includes tools, polymer and
coating, resulting in a modest manufacturing cost of £100 per
valve or less. The aluminium moulds can be machined within
12 hours and can produce hundreds of parts. Injection mould-
ing of the valve, cooling and valve extraction takes minutes.
The speed, simplicity and inexpensiveness of manufacturing
raise the intriguing future possibility of tailoring the detailed
three dimensional shape of a valve to the individual patient,
based on pre-operational imaging.
Durability. The durability of PHV prototypes was tested
according to ISO standard 5840:2015; with marked improve-
Fig. 2 A map of cylinder orientation within J6 valve and selected SAXS
images showing the microstructure oriented (a) mostly horizontally, (b)
mostly vertically and (c) cross-wise.
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ment of successive prototypes B to J6, from 13 million cycles to
>1.2 billion (p > 0.0001) (Fig. 3A). Durability was also affected
by the valve manufacturing process. Significant durability
enhancements were achieved by using a softer leaflet material
SEBS20 and shifting the injection point to the centre of the
leaflet (prototypes J4–J6) from injection onto the free edge
(prototypes B–J3).
Durability was strongly affected by leaflet thickness as
shown by the number of cycles achieved in the accelerated
tester for valves of the same design (J5 and J6) but with various
leaflet thicknesses, shown in Fig. 3B, where J6 is the valve with
optimised leaflet thickness.
The commonest failure mode of the J5 valves was formation
of a vertical crack from a free edge of the leaflet through the
injection point and down to the leaflet base. Some valves of
this type also failed due to crack formations at the
commissure.
Four valves of the latest prototype J6 (two 19 mm and two
21 mm ID) have been tested for durability. One of the 21 mm
valves (v29) failed after 783 million cycles due to a vertical
crack near the commissure in one of the leaflets. The leaflets
of this valve also showed some minor defects at the free edge.
The remaining valves have surpassed 1.1 billion (v50) and 1.2
billion cycles (v38 and v55) and are still going.
Hydrodynamic performance of each valve was measured
before fatiguing and repeated after 500 million and then every
100 million cycles. The measurements of EOA and REG are
presented in Fig. 4A and B, respectively. Beyond 500 million
cycles the opening area decreased by 10–15% compared to
before fatiguing; the EOA of the valves remained well above
the minimum required by ISO standards (0.85 cm2 for 19 mm
and 1.05 cm2 for 21 mm). The free edge of three of the valves
(v29, v38 and v50) started to show some damage beyond
500 million cycles, resulting in a somewhat increased regurgi-
tation fraction. One of the 21 mm valves (v38) started to regur-
gitate >10% at 600 million cycles and gradually worsened to
1.2 billion cycles. At 1 billion cycles one of the 19 mm valves
(v50) also exceeded the 10% regurgitation limit specified by
ISO standards for surgical valves and this continued at 1.1
billion cycles. Nevertheless after 1.1 billion (v50) and 1.2
billion cycles (v38) the regurgitation fraction was still smaller
than 20%, which is the maximum allowed by ISO for trans-
Fig. 4 Hydrodynamic performance of fatigued J6 valves. (A) Effective
Orifice Area (EOA); (B) fractional regurgitation (REG). Error bars indicate
variation between repeated measurements of the same valve.
Fig. 3 Bench durability testing: (A) durability of PHV prototypes with leaflets made from SEPS22 and SEBS20. Error bars represent one standard
deviation. Data for J6 valves does not show any variation and represents the actual state of ongoing test. (B) Durability as a function of mean leaflet
thickness for J5/J6 design. Ongoing durability testing of the J6 prototype is shown by shaded markers, while finished tests are represented by
unfilled markers.
Biomaterials Science Paper
























































































catheter valves. It is thus anticipated that valves performing in
this way would not significantly compromise the health of a
patient, while having high potential to improve it. One of the
19 mm valves (v55) at 1.2 billion cycles remained fully func-
tional as required by ISO (EOA = 1.48 cm2, REG = 5.66%).
Fatigue data for this test was collected for over 17 months at 30
Hz; 1.2 billion cycles are equivalent to over 30 years of oper-
ation at 72 bpm.
There is substantial variation in long term performance of
the four J6 valves tested for durability (most notably one of the
four failing after 783 million cycles). In general, it appears
(although with only two samples of each) that the 19 mm dia-
meter valves perform better than the 21 mm diameter ones.
This is consistent with the 19 mm valves having, pro rata,
slightly thicker leaflets than the 21 mm ones, a result of minor
mould variability. However, substantial variability remains
between notionally identical J6 valves of the same diameter;
this is ascribed to minor variations in processing conditions
during manufacture of each valve. Improved quality control to
achieve optimal performance consistently for all valves manu-
factured is an essential part of future work towards clinical
application.
Hydrodynamic performance (HP). A representative example
of the pressure and flow waveforms acquired during the pulsa-
tile test (5 l min−1, 70 bpm) of our latest design (J6) valve is
presented in Fig. 5B.
Fig. 5C–E shows the hydrodynamic performance of designs
J5 and J6, which are geometrically identical with the exception
of leaflet thickness. Five pairs of aluminium mould inserts
were used to manufacture valves having average leaflets thick-
ens of 0.24 mm, 0.30 mm, 0.35 mm, 0.40 mm and 0.46 mm,
but otherwise identical geometry, so the effect of the thickness
could be assessed independent of other factors. Six 21 mm
valves of each thickness were tested in the pulse duplicator
system. All valves exceeded minimum ISO standard require-
ments. Leaflet thickness markedly affected hydrodynamic per-
formance, especially EOA, which reduced from 2.5 cm2 to
1.1 cm2 with increasing leaflet thickness from 0.24 mm to
0.46 mm (Fig. 5C). Mean pressure gradient ΔP also consider-
ably increased (from 8 to 25 mmHg) as the thickness increased
(Fig. 5E). Test data for REG was more scattered, due to
occasional paravalvular leak in the valve housing system, but
the general trend showed a drop in regurgitation fraction with
increasing thickness of the leaflets (Fig. 5D).
Comparison of PHV vs. BIC-B. The measured hydrodynamic
performance of the BIC-B (Carpentier-Edwards Perimount
Pericardial Bioprosthesis) is also shown in Fig. 5C–E. The EOA
and mean ΔP of the BIC-B are similar to those of the PHVs
with leaflet thickness of 0.35–0.40 mm (coincidentally approxi-
mately the same as the thickness of the pericardium tissue
making up the leaflets of the BIC-B).
Snapshots of the PHV and the BIC-B at peak diastole and
systole are shown in Fig. 5A, allowing a comparison of the
opening area at peak systole, as well as the shape of the fully
open orifice for both polymeric (J6) and reference valves. The
PHV showed a more circular opening and its geometrical
opening area at peak systole was 15% larger than for the Perimount
valve. The calculated mean values of EOA for the J6 21 mm PHV (n
Fig. 5 Measurements of hydrodynamic performance: (A) prototype J6 21 mm and Edwards Perimount 21 mm valve at peak systole (left) and dia-
stole (right); (B) pressure and flow waveforms acquired during pulsatile tests of J6 valve: AP is aortic pressure, LVP left ventricular pressure, and AF
aortic flow; (C) Effective Orifice Area (EOA); (D) regurgitant fraction (REG); (E) mean systolic pressure gradient ΔP. Error bars represent one standard
deviation. The trend line catches the effect of leaflet thickness on hydrodynamics of 21 mm polymeric valves. Results for the J6 valve (21 mm) are
circled by a dashed line; the 19 mm J6 valve selected for in vivo testing is represented by red markers. All data are prior to fatiguing.
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= 6) was 1.77 ± 0.05 cm2, which was almost the same as for the
reference valve (n = 2) 1.76 ± 0.13 cm2. The inconsistence between
the geometrical and calculated opening area can be explained by
different dynamics of opening for the two types of valve.
To guarantee good size-matching for the aortic annulus of a
typical 70–80 kg adult sheep for preliminary in vivo short-term
evaluations, two sizes of the J6 valve were prototyped: 21 mm
and 19 mm internal diameter. The hydrodynamic performance
of these two sizes of prototype J6, as well as the reference
BIC-B 21 mm is shown in Table 3.
Haemocompatibility
The images from polymer samples treated in the Badimon
chamber at high (1920 s−1; Re 60) and low shear (500 s−1; Re
30) (Fig. 6) did not show thrombus aggregation as typically
seen when using porcine aorta as the thrombogenic
substrate.29–31 We were unable to perform quantitative analysis
given the absence of thrombus. Qualitatively, a thin layer of
fibrin and/or red blood cells were seen in the samples. The
images shown are from heparin coated samples; uncoated
samples were also tested, with similar results. Previous work
has shown that heparin coating of similar block copolymers
reduces the thrombogenicity of surfaces.24 The Badimon
chamber technique was not able to resolve this difference, but
it did confirm that all samples (heparin coated and uncoated)
showed good haemocompatibility.
The durability of heparin coating was assessed in vitro; in pre-
vious work24 it was shown, by XPS monitoring of surface sulphur,
to be stable over 500 hours in a variety of solutions, with or
without dynamic strain. Only a strongly oxidising solution (3%
aqueous H2O2) resulted in rapid loss of surface coating. Using the
same XPS technique, we have shown that a heparin coated valve
retains 60% of its surface sulphur after 190 million cycles (4.5
years equivalent) in the accelerated fatigue tester.
Preliminary clinical feasibility evaluations
Extra-vivo developmental/feasibility evaluations. Extra-vivo
refinement of the PHV focused on 3D shape, low profile, exter-
nal diameter, flexibility/elasticity and suturability: findings
from representative experiments are shown in Fig. 7A–C. We
undertook a series of surgical implantations and size-match-
ing procedures (n = 8) on pre-sized aortic annulus in porcine












n = 7 1.42 ± 0.04 3.82 ± 0.47 16.19 ± 1.01 30.69 ± 1.74
Polymeric
21 mm
n = 6 1.77 ± 0.05 3.40 ± 1.10 10.41 ± 0.66 22.94 ± 1.33
Bioprosthetic
21 mm
n = 2 1.76 ± 0.13 2.13 ± 0.76 11.90 ± 1.87 23.68 ± 1.05
Values are shown as mean ± standard deviation.
Fig. 6 Images taken from samples treated in the Badimon chamber: (A) a heparin coated (Corline) sample placed in a high shear chamber showing
no thrombus; (B) a heparin coated (Corline) sample placed in a low shear chamber showing small clumps of red blood cells and fibrin; (C) a heparin
coated (Corline) sample placed in a high shear chamber showing small clumps of red blood cells and some fibrin staining; (D) a heparin coated
sample (Biointeractions) placed in a high shear chamber showing red blood cells and fibrin; (E) a heparin coated sample (Biointeractions) placed in a
low shear chamber showing red blood cells and fibrin; (F) images from earlier experiments31 showing thrombus formation over porcine aorta
stripped of intima (SEM = scanning electron microscopy). Optical images were taken at ×10 magnification, SEM at ×100 000.
Biomaterials Science Paper
























































































hearts/cadavers, informing the changes implemented from
PHVs prototype J3 (Fig. 7A) then J4 (Fig. 7B), to prototype J6
(Fig. 7C). The external diameter of a typical PHV with an
internal diameter of 21 mm was reduced from 32 mm to
25 mm (Fig. 7A vs. 7C). The base shape changed from 2D flat
to 3D saddle-shape to reflect the 3D lining of the porcine/
human aortic valve annulus, while the height/profile was
reduced to 13 mm (Fig. 1B). The consistency of the PHV
changed from rigid/semi-rigid to flexible/elastic (see Video 3;
ESI†) to reflect the need to preserve the physiologic dynamics
of the native valvular annulus after implant. A fabric-free valve
suturing system was achieved, based on 12–14 pairs of holes
(0.5 mm diameter) as shown in Fig. 1B and C, which allowed
excellent extra-vivo implantation of J6 (n = 4) without defor-
mation (Fig. 7C).
Extra-vivo compatibility to magnetic resonance imaging
(MRI) was assessed by suturing two PHVs in two porcine
hearts in aortic (Fig. 7D upper) and mitral positions (Fig. 7D
lower). The PHV inserted in the mitral position was intention-
ally sutured over the native mitral valve to allow direct com-
parative imaging evaluations with the native leaflets. This
experiment showed excellent MRI compatibility of the PHV,
and allowed a detailed morphological assessment of the PHV
with no artefacts. Finally, the compatibility of the PHV with
clinical sterilisation techniques was assessed by bench based
evaluation with and without sterilisation, and the durability
and hydrodynamic performance of the sterilised PHV was not
adversely affected (data provided in ESI, Table S2†).
In vivo short-term feasibility evaluation. The in vivo short-
term feasibility study was carried out in 75–80 kg sheep in a
model of cardiac surgery with CPB and CA through left thora-
cotomy (n = 3) with a recovery time ranging from 1 (n = 2) to
24 hours (n = 1). In all cases a 19 mm J6 PHV was inserted in
supra-annular fashion using 4-0 prolene sutures (Fig. 8A). In
vivo echocardiographic evaluations (n = 3) were recorded at
1 hour post-surgery, with an ongoing average systolic blood
pressure of 96 ± 8 mmHg. There was no evidence of any peri-
valvular or trans-valvular regurgitation as seen in Fig. 8B (and
Videos 4 and 5, ESI†). Measurements of the average trans-valv-
ular peak gradient (Fig. 8C) indicated 23 ± 3 mmHg, in
keeping with the bench-based hydrodynamic performance of
the 19 mm J6 PHV. One of these 3 animals was kept for
24 hours after completion of surgery and extubated success-
fully for post-extubation safety assessment of short-term valvu-
lar integrity and biocompatibility. This animal was not antic-
oagulated and received only Aspirin 300 mg day−1. Post-
mortem confirmed intact structure of the PHV with no evi-
dence of any acute valvular clot/thrombus.
Discussion
This study has several key findings. It shows that it is possible
to use styrenic block copolymers to make a PHV as an alterna-
tive to mechanical and biological prostheses. PHV develop-
ment required the implementation of refinements in design
based on computational modelling (reported previously),18
in vitro testing and clinician/surgical feedback, leading to suc-
cessive prototypes manufactured by a highly reproducible (and
inexpensive) injection moulding technique. The most recent
PHV J6 prototype markedly exceeds the ISO standards in terms
of hydrodynamic performance and durability. PHV J6 under-
went in vivo preliminary short-term feasibility testing with very
encouraging safety, functional and biocompatibility outcomes,
supporting its progression into an experimental randomised
trial, which has just started.
Inspired by the native valve, in which collagen fibres are
aligned to bear stresses during loading, we utilised oriented
styrene cylinders in block copolymers to reinforce the poly-
meric leaflets. Mechanical properties of the materials can be
tailored by controlling microstructural alignment, which
strongly depends on flow direction within the mould.
Fig. 7 Representative illustrations of PHV prototypes during development (upper panels) and aligned extra-vivo procedures (lower panels): (A) pro-
totype J3; (B) prototype J4; (C) prototype J6; (D) MRI compatibility: longitudinal view of PHV sutured in aortic position (upper panel, white arrow)
and mitral position (lower panel, white arrow); note native mitral leaflets (yellow arrows) for imaging comparison with PHV.
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Mapping of cylinders’ orientation within leaflets of J6 revealed
orientation of cylinders similar to the orientation of collagen
fibres in native heart valve tissue.13,14 Our finite element mod-
elling, previously reported, demonstrates the importance and
advantages of well controlled anisotropy versus anisotropic
polymer,18 with the former showing smaller strain and smaller
strain energy density, which is directly related to durability.
Experimental comparison of oriented and isotropic heart valve
leaflets using accelerated fatigue tester was not possible,
because it is very difficult to obtain isotropic samples using
our manufacturing method. Moreover the performance of the
valve results not only from the leaflet material microstructure
but also from optimisation of its geometry and properties of
its components. The microstructure orientation present in
J6 has the closest analogy to the native heart valve anisotropy
of all our prototypes.
The excellent bench durability achieved with the J6 proto-
type is also the result of progressive refinements (Fig. 3A). The
early PHV prototypes showed insufficient durability (whilst
achieving good hydrodynamic performance) with leaflet tears
developing within a few tens of millions of cycles. We learned
that PHV durability is not only a function of the polymer
selected for leaflet construction, but is also highly dependent
on valve design and manufacturing process. For example, it
was enhanced by using a leaflet material (SEBS20) with better
fatigue properties and by shifting the injection point to the
centre of the leaflet instead of the free edge (prototypes B–J3).
In addition, leaflet thickness was shown to be a critical para-
meter affecting both durability and hydrodynamic perform-
ance. Indeed, the number of cycles achieved in the accelerated
tester for PHVs of the same design (J5 and J6) but with various
leaflet thicknesses increased significantly with increasing
leaflet thickness. Unsurprisingly, whilst thicker leaflets per-
formed better in terms of durability, their opening area and
transvalvular pressure gradient worsened (Fig. 6C and E). The
best performing prototype J6 has a design capturing the
optimal balance between these two key design requirements.
In on-going durability testing, three of four J6 valves begin to
show free edge fracture above 500 million cycles resulting in
increased regurgitation, although all remain functional.
Further geometrical optimisation of leaflets height, coaptation
and thickness near the fee edge, is likely to improve the free
edge resistance to damage. Nevertheless, the durability already
achieved greatly exceeds the ISO requirement, which is
200 million cycles.
Calcification can be an important contributor to valve
degeneration in vivo and its molecular mechanisms are
difficult to reproduce in vitro. However, a recent study shows
that a styrenic block copolymer is significantly less prone to
calcification in vitro than is a polyurethane valve.36
Hydrodynamic testing is subject to considerable variation
depending on the details of geometry and testing conditions
used, i.e. the same valve can give different results when tested
in different pulse duplicators under ostensibly similar con-
ditions; for example the shape and flexibility of the outflow
pipe affect the EOA measured.37 For this reason, the hydrodyn-
amic testing was compared to identical tests in the same
equipment performed on the BIC-B of nominal diameter
21 mm (measured internal diameter 20 mm, measured exter-
nal sewing ring diameter 29 mm), which is commonly con-
sidered a gold standard reference valve. Of note, the Edwards
Perimount, which we used as BIC-B, showed slightly lower
(although within the error bars) REG fraction (2.13 ± 0.76%)
than the J6 PHV prototype (3.40 ± 1.10%), well below 10%, the
ISO requirement for a 21 mm valve. Our bench-based results
for the Edwards Perimount valve are similar to those reported
by others for the same valve tested in vitro38,39 and in vivo.40,41
Based on these experimental bench-test results, supported
by structural FEM modelling (reported elsewhere18), leaflet
thickness of 0.4 mm (prototype J6) was selected for feasibility
short-term evaluation in a sheep model of cardiac surgery.
Extra-vivo clinical testing was of great value during the
development process in picking up limitations of the early pro-
totypes and suggesting refinements to the design to improve
the external diameter, 3D shape, profile, flexibility/elasticity,
suturability and handling, while checking the compatibility to
MRI imaging and clinical sterilisation. In addition, the pre-
liminary in vivo short-term testing confirmed basic functional
Fig. 8 Representative in vivo feasibility experiment using a J6 19 mm PHV with animal recovered and kept for 24 hours post-surgery: (A) PHV
during (top) and after (bottom) suturing in aortic position; (B) end-diastolic echo-Doppler at 1 hour post-surgery showing no trans-valvular or peri-
valvular jets in transverse (top left) and longitudinal (bottom left) views; end-systolic echo Doppler at 1 hour post-surgery showing blood flow across
the opened PHV in transverse (top right) and longitudinal (bottom right) views; (C) measurement of transvalvular peak gradient (24 mmHg in this
case) at the same time point.
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safety/feasibility on the J6 prototype in terms of early hydro-
dynamic performance (n = 3, echocardiography at 1 hours
post-surgery) and biocompatibility (n = 1, post-mortem evalu-
ation at 24 hours post-surgery). We used only 19 mm PHVs as
this size is the smallest generally used in adult cardiac surgery,
whilst in our in vivo model the aortic annulus/root of the
75–80 kg sheep used would not take a larger PHV without root
enlargement. As a result of this positive safety/feasibility pilot
study we are progressing into an experimental trial assessing
the long-term performance of our PHV. This trial involves
implantation into adult sheep recovered for six months with a
focus on valve in vivo biocompatibility, haemodynamics, dura-
bility and susceptibility to calcification.
For the single in vivo experiment focusing on early biocom-
patibility/thrombosis the animal was kept for 24 hours after
surgery on 300 mg of Aspirin per day without anticoagulation.
Histopathology confirmed an intact PHV with no clots/throm-
bus at 24 hours, suggesting good short-term biocompatibility.
This is in keeping with our observations in vitro where no
thrombus collection was observed in either the heparin coated
or the uncoated samples and as such, no quantification of
thrombus amount was possible. Whilst the standard flow rate
through the chamber was 10 mL per minute of blood for
5 minutes, it is reassuring to note that compared to porcine
aorta (intima stripped) there were no thrombus clumps seen
in any of the samples.
The work reported in this paper relates to development of a
surgical valve. However much of what has been learnt can be
transferred directly into a trans-catheter device, which we are
at present in the early stages of developing, incorporating iden-
tical leaflets to the surgical valve.
Conclusions
A PHV valve has been developed and tested in vitro, and in a
short-term in vivo study. The final prototype is an over-
moulded composite of a stiffer support structure (made of
SEBS29) and softer leaflets (made of SEBS20), incorporating
cylindrically shaped leaflets with a concave leading edge
profile. This is performing excellently, well beyond ISO
5840:2015 standards for in vitro performance and equivalent
to the same diameter Edwards Perimount Bioprosthetic valve
in hydrodynamic performance, with durability in excess of 1.2
billion cycles, equivalent to 30 years of operation. In addition,
the prototype has passed preliminary feasibility in vivo short-
term testing with very good haemodynamic and biocompatibil-
ity performance.
Abbreviations
PHV Prosthetic heart valve
STCP Styrenic triblock copolymer
SEPS Poly(styrene-block-ethylene/propylene-block-styrene)
SEBS Poly(styrene-block-ethylene/butylene-block-styrene)
BIC-B Best-in-class bio-prosthesis (Carpentier-Edwards
Perimount Pericardial Bioprosthesis)
SEBS20 SEBS having 20 wt% styrene content
SEBS29 SEBS having 29 wt% styrene content
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